Mario Gaudino1*, MD; Umberto Benedetto2, PhD; David P. Taggart3, PhD
1. Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA; 2. Bristol Heart Institute, University of Bristol, School of Clinical Sciences, Bristol, United Kingdom; 3. University of Oxford, Oxford, United Kingdom
In this issue of EuroIntervention Kjøller-Hansen and colleagues report the results of a post hoc analysis of the SORT OUT II trial comparing the 10-year rate of a composite outcome of death, myocardial infarction and repeat revascularisation between patients receiving a single drug-eluting stent in the proximal left anterior descending (LAD) vs. non-proximal LAD1. The authors report no difference between the two groups (HR 0.82, 95% CI: 0.65-1.03).
The analysis has some limitations. The definition used by the authors is somewhat arbitrary and difficult to understand: why not compare LAD vs. non-LAD lesions? Why group the distal LAD with ...